Clifford Swan Investment Counsel LLC Purchases 137 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Clifford Swan Investment Counsel LLC raised its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,187 shares of the medical equipment provider’s stock after acquiring an additional 137 shares during the period. Clifford Swan Investment Counsel LLC’s holdings in Intuitive Surgical were worth $620,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. M.E. Allison & CO. Inc. bought a new stake in shares of Intuitive Surgical during the fourth quarter worth approximately $449,000. Seilern Investment Management Ltd acquired a new stake in Intuitive Surgical during the fourth quarter worth approximately $82,517,000. Sycomore Asset Management grew its position in Intuitive Surgical by 27.4% during the fourth quarter. Sycomore Asset Management now owns 18,945 shares of the medical equipment provider’s stock worth $9,214,000 after buying an additional 4,079 shares in the last quarter. Exome Asset Management LLC grew its position in Intuitive Surgical by 16.8% during the third quarter. Exome Asset Management LLC now owns 7,427 shares of the medical equipment provider’s stock worth $3,649,000 after buying an additional 1,069 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Intuitive Surgical by 5.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,843 shares of the medical equipment provider’s stock worth $5,138,000 after buying an additional 525 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 1.7 %

Shares of NASDAQ:ISRG opened at $573.15 on Monday. The firm has a market cap of $204.14 billion, a P/E ratio of 89.42, a P/E/G ratio of 5.85 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00. The business has a fifty day simple moving average of $569.87 and a 200 day simple moving average of $529.47.

Insider Buying and Selling

In related news, CFO Jamie Samath sold 270 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total transaction of $145,840.50. Following the completion of the transaction, the chief financial officer now directly owns 8,757 shares of the company’s stock, valued at $4,730,093.55. This trade represents a 2.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the sale, the director now owns 12,275 shares of the company’s stock, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,077 shares of company stock valued at $4,620,025 in the last three months. Insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ISRG shares. Royal Bank of Canada increased their price target on Intuitive Surgical from $611.00 to $641.00 in a research report on Monday, January 27th. Evercore ISI upped their target price on Intuitive Surgical from $490.00 to $530.00 in a research note on Monday, January 27th. Bernstein Bank upped their target price on Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. Citigroup upped their target price on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Finally, CICC Research initiated coverage on Intuitive Surgical in a research note on Monday, January 27th. They set a “neutral” rating and a $550.00 target price for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average price target of $613.10.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.